EPFL researchers have successfully engineered cells of the immune system to more effectively recognize cancer cells. The work, covered in two papers, turns the previously lab-based method into a ...

This is especially true after immunotherapy. Increasing our basic insights on dendritic cell biology will help us to restore the networks of these cells in tumors and thereby tailor optimal therapies ...

Cancer immunotherapy is a strategy that turns the patient’s own immune cells into a “search-and-destroy” force that attacks the tumor’s cells. The “search” immune cells are the dendritic cells, which ...

The immune system consists of inflammatory and regulatory T cells (Tregs) that promote or dampen immune activity, respectively. These cells react to specific antigens that specialized cells like ...

Immunotherapy has emerged as a promising alternative in cancer treatment to traditional chemotherapy, offering gentler treatment options with fewer side effects for cancer patients. However, ...

A dendritic cell vaccine administered before and after autologous stem cell transplant (ASCT) was safe and immunogenic and was associated with durable clinical responses in patients with high-risk ...

BPDCN is an aggressive type of blood cancer that originates from plasmacytoid dendritic cells (pDCs), a component of the immune system that produces type 1 interferon cytokines. These cytokines help ...

Cancer immunotherapy transforms a patient’s immune cells into a “search‑and‑destroy” force against tumors. But many cancers learn to camouflage themselves from dendritic cells—the immune system’s ...